TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03986294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 + Nal-IRI
Description: S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI+Leucovorin+5-FU
Description: Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
Study: NCT03304587

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG)
Description: Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography (PSG)
Description: Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rectal thermistor 400 Series
Description: Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rectal thermistor 400 Series
Description: Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
Study: NCT03986294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI+Leucovorin+5-FU
Description: Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
Study: NCT02532543

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allograft, Membrane
Description: Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
Study: NCT02532543

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alloplast, Membrane
Description: Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft, Membrane
Description: Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Membrane
Description: Membrane - Symbios OsteoShield Collagen Resorbable Membrane
Study: NCT03524872

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Original CAD/CAM prosthetic abutment
Description: Original (Sweden\&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compatible CAD/CAM abutment
Description: Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
Study: NCT01410227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF)
Description: Intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF)
Description: Intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF)
Description: Intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF)
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Syringe supplied with physiologic saline solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Syringe supplied with physiologic saline solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIII (rFVIII)
Description: Intravenous administration
Study: NCT03304587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression
Description: 8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function
Description: 8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function
Description: 8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
Study: NCT01410227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIII (rFVIII)
Description: Intravenous administration
Study: NCT05421403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenotonsillectomy
Description: all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade \>2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of \~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
Study: NCT03524872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Description: Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Painkillers
Description: Patients will be prescribed ibuprofen 600 mg three times per day for five days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Painkillers
Description: Patients will be prescribed ibuprofen 600 mg three times per day for five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwashes
Description: Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
Study: NCT02972762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Description: anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Description: anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
Study: NCT03444987

Intervention type: GENETIC
Intervention: Measurement of protein expression in tissues.
Description: The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method

Intervention type: GENETIC
Intervention: Measurement of protein expression in tissues.
Description: The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method
Study: NCT04380636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for olaparib
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study: NCT01976611

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
Study: NCT01924403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staple Closure
Study: NCT04380636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Radiotherapy
Description: external beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: external beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: external beam radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: IV infusion
Study: NCT03256656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials
Study: NCT04635670

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pro-/prebiotic Mix
Description: Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
Study: NCT01410227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIII (rFVIII)
Description: Intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIII (rFVIII)
Description: Intravenous administration
Study: NCT00776763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin intravitreal injection
Description: 1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
Study: NCT01429363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted disc decompression
Description: The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
Study: NCT04865003

Intervention type: OTHER
Intervention: treatment of infection

Intervention type: OTHER
Intervention: treatment of infection
Study: NCT01983501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib (ONT-380)
Description: Given twice per day, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Given intravenously once every 21 days
Study: NCT01688011

Intervention type: DRUG
Intervention: Luspatercept
Description: Prescribed by treating physician as per product label.
Study: NCT03151577

Intervention type: PROCEDURE
Group type: OTHER
Intervention: XEN® Gel Stent implantation
Description: Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
Study: NCT05606458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: İntervention Group
Description: Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
Study: NCT01022983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosimendan
Description: At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ml/kg/hours - same infusion rate as active comparator
Study: NCT01496495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-614, p38/Tie2 inhibitor; oral
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
Study: NCT02922569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Thirty minutes of training on computerized, casual video games.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traumatic Brain Injury Information Session
Description: Ten minutes of viewing traumatic brain injury related news, information, and programs.
Study: NCT02121067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS)
Description: The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
Study: NCT03524872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwashes
Description: Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
Study: NCT03976232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans cranial Direct Current Stimulation (tDCS)
Description: Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (CST)
Description: Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS+ CST
Description: This group will receive tDCS along with CST
Study: NCT02120586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT).
Description: Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral muscle training
Description: The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10.
Study: NCT04635670

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soluble powder for oral use twice daily.
Study: NCT02879240

Intervention type: OTHER
Group type: OTHER
Intervention: Animated Cartoon
Description: An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.

Intervention type: OTHER
Group type: OTHER
Intervention: Animated Cartoon
Description: An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.

Intervention type: OTHER
Group type: OTHER
Intervention: Black screen
Description: A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.

Intervention type: OTHER
Group type: OTHER
Intervention: Black screen
Description: A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.